Performance of <sup>18</sup>F-FDG PET/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer.

iScience · 2024 · PMC11059538 · PMID 38689640

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

made a retrospective investigation to the feasibility of using MRI and 18 F-FDG-PET/CT in N staging and found that no significant difference was found between MRI and 18 F-FDG-PET/CT for the BLCA N staging but a slight trend of advantage of 18 F-FDG-PET/CT compared with MRI alone, which also indicated the value of the addition of PET information for the enhanced efficacy of N staging in BLCA.

also in 2,235 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.